Small Animal Imaging Market Size, Share & Forecast 2026–2035
What Is the Small Animal Imaging Market Size?
The global Small Animal Imaging market was valued at USD 3.2 Billion in 2025 and is projected to grow from USD 3.4 Billion in 2026 to USD 6.4 Billion by 2035, at a CAGR of 7.2% from 2026–2035.
Small Animal Imaging Market Key Takeaways
According to Healthcare Industry Insights analysis, the market's expansion will be shaped by the steady conversion of terminal preclinical studies into longitudinal in vivo imaging workflows, with software-led image analysis capturing a growing share of total spending over the coming decade.
What Does the Small Animal Imaging Market Encompass?
The Small Animal Imaging market covers the hardware, software, and consumable ecosystem used to visualize, quantify, and monitor physiological and pathological processes in laboratory rodents and companion animals. Structural evolution has moved the sector from standalone modality purchases toward integrated multimodal platforms and cloud-enabled analysis. Regulatory frameworks such as EU Directive 2010/63 on the protection of animals used for scientific purposes reinforce the shift toward non-invasive refinement and reduction.
Parameter Description
| Parameter | Details |
|---|---|
| Market Size in 2025 | USD 3.2 Billion |
| Market Size in 2026 | USD 3.4 Billion |
| Revenue Forecast in 2035 | USD 6.4 Billion |
| Growth Rate | CAGR of 7.2% from 2026 to 2035 |
| Analysis Period | 2025–2035 |
| Base Year Considered | 2025 |
| Forecast Period | 2026–2035 |
| Market Size Estimation | Revenue (USD Billion) |
| Companies Profiled | 20 Profiled |
| Countries Covered | 38 Countries |
| Market Share | Available for Top 10 Companies |
Key Emerging Trends in the Small Animal Imaging Market
Based on research conducted by Healthcare Industry Insights, we found that four structural trends are reshaping product development, sourcing, and stakeholder engagement across the Small Animal Imaging industry.
Growth Drivers, Restraints & Opportunities
The following interactive matrix outlines the primary forces shaping the Small Animal Imaging market through 2035, categorized by qualitative impact level, geographic relevance, and projected timeline. Type in the search box to filter by driver, restraint, or opportunity.
| Factors ▲ | Type | Qualitative Impact | Geographic Focus | Timeline |
|---|---|---|---|---|
| Oncology pipeline expansion | DRIVER | High | Sustains demand for tumor progression monitoring across pharma R&D | 2026–2035 |
| 3Rs regulatory mandates | DRIVER | High | Accelerates adoption of longitudinal non-invasive imaging over terminal endpoints | 2026–2035 |
| CRO capacity build-out in Asia-Pacific | DRIVER | Medium | Expands installed base in India, China, and Japan | 2026–2030 |
| Software and AI-enabled analysis | DRIVER | Medium | Raises per-study analytical value and recurring software revenue | 2026–2035 |
| Currency volatility and import tariffs | RESTRAINT | Medium | Constrains purchasing in Latin America and parts of emerging markets | 2026–2030 |
| High capital cost of multimodal systems | RESTRAINT | Medium | Limits adoption among small academic and veterinary clinics | 2026–2035 |
How Do Compliance Mandates Anchor Baseline Demand?
Based on research conducted by our analysts, we found that 3Rs-driven refinement requirements under EU Directive 2010/63 act as a demand anchor and compliance floor for imaging adoption. These mandates guarantee baseline utilization across European facilities regardless of cyclical R&D spending. They do not, however, represent the market's primary growth engine, which lies in high-CAGR emerging segments such as software and Asia-Pacific capacity expansion.
Which Factors Act as the Primary Growth Vectors?
Healthcare Industry Insights's analysis indicates that growth vectors concentrate in software-led analytics, veterinary and gene therapy tracking, and Middle East and Asia-Pacific capacity build-outs. Software is projected to expand at 10.0% CAGR, veterinary applications at 5.7%, and Middle East and Africa at 11.4% over the 2026–2035 forecast period. These emerging vectors carry faster compounding than the mature North American installed base at 5.7% CAGR.
What Restraints Could Slow Market Expansion?
Our findings suggest that currency volatility and import tariffs in Latin America, together with the high capital cost of multimodal systems, will moderate adoption in price-sensitive institutions. Latin America is projected to grow at 8.0% CAGR over the 2026–2035 forecast period, reflecting these constraints. Buyers in these markets increasingly favor refurbished systems and shared-access facilities to manage capital exposure.
Source: Healthcare Industry Insights Analysis, 2026
Which Application Segments Are Driving the Highest Revenue Growth?
Segment Sizing: By Offering
Within the By Offering category, the Preclinical Imaging Hardware (Optical, MRI, PET/SPECT, CT and Ultrasound Systems and Detectors) segment held the dominant market share in 2025. Meanwhile, the Reconstruction, Quantification and Analysis Software with AI/Algorithmic Image Processing segment is anticipated to be the fastest-growing, expanding at a CAGR of 12.7% during the forecast period.
| Segment Item | 2025 (USD Bn) | 2026 (USD Bn) | 2035 (USD Bn) | CAGR (2026–2035) |
|---|---|---|---|---|
| Preclinical Imaging Hardware (Optical, MRI, PET/SPECT, CT and Ultrasound Systems and Detectors) | 1.98 | 2.06 | 3.14 | 4.8% |
| Reconstruction, Quantification and Analysis Software with AI/Algorithmic Image Processing | 0.64 | 0.72 | 2.11 | 12.7% |
| Imaging Contrast Agents, Probes, Animal Handling Accessories and Integration/Validation Services | 0.58 | 0.62 | 1.15 | 7.1% |
| Total | 3.2 | 3.4 | 6.4 | 7.2% |
Source: Healthcare Industry Insights Analysis, 2026
Segment Sizing: By Application
Within the By Application category, the Oncology Drug Discovery and Tumor Progression Monitoring segment held the dominant market share in 2025. Meanwhile, the Veterinary Diagnostics, Companion Animal Imaging and Gene/Cell Therapy Tracking segment is anticipated to be the fastest-growing, expanding at a CAGR of 11.5% during the forecast period.
| Segment Item | 2025 (USD Bn) | 2026 (USD Bn) | 2035 (USD Bn) | CAGR (2026–2035) |
|---|---|---|---|---|
| Oncology Drug Discovery and Tumor Progression Monitoring | 1.22 | 1.27 | 2.11 | 5.8% |
| Neuroscience and Cardiovascular Disease Modeling | 0.86 | 0.91 | 1.66 | 6.9% |
| Toxicology, Pharmacokinetics and Biodistribution Safety Assessment | 0.61 | 0.64 | 1.09 | 6.1% |
| Veterinary Diagnostics, Companion Animal Imaging and Gene/Cell Therapy Tracking | 0.51 | 0.58 | 1.54 | 11.5% |
| Total | 3.2 | 3.4 | 6.4 | 7.2% |
Source: Healthcare Industry Insights Analysis, 2026
Segment Sizing: By End-User
Within the By End-User category, the Pharmaceutical and Biotechnology Companies (Internal Preclinical R&D Programs) segment held the dominant market share in 2025. Meanwhile, the Contract Research Organizations and Imaging Service Providers segment is anticipated to be the fastest-growing, expanding at a CAGR of 9.6% during the forecast period.
| Segment Item | 2025 (USD Bn) | 2026 (USD Bn) | 2035 (USD Bn) | CAGR (2026–2035) |
|---|---|---|---|---|
| Pharmaceutical and Biotechnology Companies (Internal Preclinical R&D Programs) | 1.41 | 1.49 | 2.62 | 6.5% |
| Contract Research Organizations and Imaging Service Providers | 1.06 | 1.15 | 2.62 | 9.6% |
| Academic, Government and Veterinary Teaching/Clinical Institutions | 0.73 | 0.76 | 1.16 | 4.8% |
| Total | 3.2 | 3.4 | 6.4 | 7.2% |
Source: Healthcare Industry Insights Analysis, 2026
Key Market Segments
The complete segmentation hierarchy used throughout this report. Click a category to view its sub-segments.
Growth Opportunities
Our analysis shows that three forward-looking opportunities stand out for stakeholders positioning within this market over the forecast period.
Where Can Providers Capture Software-Led Value?
Our findings suggest that vendors offering validated AI-based reconstruction and quantification packages can capture recurring revenue from installed hardware bases. Software is projected to reach USD 2.11 Billion by 2035, making it the most attractive whitespace for analytics-focused entrants.
Which Asia-Pacific Markets Offer Capacity Expansion?
We found that China, India, and Japan are building preclinical imaging capacity alongside domestic biopharma R&D. Asia-Pacific is projected to expand from USD 0.7 Billion in 2025 to USD 1.82 Billion by 2035, creating whitespace for service-led and localized deployment models.
How Can Veterinary Imaging Access Be Widened?
Our assessment indicates that companion animal imaging remains underserved in mid-sized clinics. Affordable, shared-access imaging services and compact systems could address this gap, supporting the veterinary application's projected 11.5% CAGR over 2026–2035.
Investment Opportunities
Capital Inflows
Capital is flowing toward software-led analytics and multimodal platform development, as investors seek recurring revenue streams beyond hardware cycles. Partnerships between imaging OEMs and agent developers signal confidence in integrated offerings that can justify premium valuations over the forecast period.
Infrastructure
Shared-access imaging cores and CRO expansions in India, China, and the Middle East create infrastructure investment opportunities. Facilities that pair multimodal hardware with validated analysis pipelines are positioned to capture outsourced preclinical volume.
ESG
Non-invasive longitudinal imaging aligns with 3Rs principles and reduces animal use per study. Investors evaluating animal welfare compliance and research efficiency increasingly view these attributes as material to long-term operational risk.
SWOT Analysis
Our assessment indicates that the following strengths, weaknesses, opportunities, and threats characterize the competitive position of the Small Animal Imaging heading into 2035.
The market benefits from a dense installed base of preclinical hardware, established OEM technical service networks, and entrenched adoption in pharmaceutical oncology and neuroscience pipelines across North America and Europe.
High capital costs of multimodal systems, long replacement cycles, and fragmented software interoperability across vendors limit adoption among smaller academic and veterinary institutions.
Software-led quantification, veterinary and gene therapy tracking, and capacity build-out in Asia-Pacific and Middle East and Africa offer high-growth pathways through 2035.
Currency volatility and import tariffs in Latin America, potential R&D budget contractions in pharmaceutical sponsors, and competitive pricing pressure from regional manufacturers could compress margins.
Access the Full Market Report
38 Countries · 20 Profiled · 10-year forecast with YoY data tables · Free Excel data file included
Regional Outlook
Click a region to explore its key national markets and growth drivers.
North America was valued at USD 1.33 Billion in 2025 and estimated at USD 1.39 Billion in 2026, reaching USD 2.29 Billion by 2035 at a 5.7% CAGR (2026–2035). We found that the region's dense concentration of preclinical CROs and NIH-funded vivarium infrastructure sustains its position as the largest installed base, although its share narrows as Asian capacity scales.
United States
CanadaEurope was valued at USD 0.93 Billion in 2025 and estimated at USD 0.98 Billion in 2026, reaching USD 1.7 Billion by 2035 at a 6.3% CAGR (2026–2035). Our assessment indicates that imaging OEMs in Germany, the UK, and France, combined with 3Rs refinement mandates, steadily shift research toward longitudinal in vivo imaging and away from terminal endpoints.
Germany
United Kingdom
FranceAsia-Pacific was valued at USD 0.1 Billion in 2025 and estimated at USD 0.11 Billion in 2026, reaching USD 0.29 Billion by 2035 at a 10.0% CAGR (2026–2035). We observed that China's biopharma expansion, India's CRO build-out, and government-backed life sciences infrastructure in Japan, South Korea, and Australia position the region for the fastest regional compounding this decade.
China
India
Japan
South Korea
AustraliaLatin America was valued at USD 0.14 Billion in 2025 and estimated at USD 0.15 Billion in 2026, reaching USD 0.3 Billion by 2035 at a 8.0% CAGR (2026–2035). Based on research conducted by our analysts, we found that Brazil's veterinary oncology and academic research sectors support steady demand, tempered by currency volatility and import tariffs that affect capital equipment purchasing.
Brazil
ArgentinaMiddle East & Africa was valued at USD 0.1 Billion in 2025 and estimated at USD 0.11 Billion in 2026, reaching USD 0.29 Billion by 2035 at a 11.4% CAGR (2026–2035). Healthcare Industry Insights's analysis indicates that Saudi Arabia's Vision 2030 localization programs and UAE genomics investments are building new preclinical imaging capacity from a small base, making this region the smallest by volume in 2026 but among the fastest in relative expansion.
Saudi Arabia
UAE
South AfricaCompetitive Landscape
Our findings suggest that the market is moderately concentrated, with leading hardware manufacturers holding significant installed bases. Competitive intensity is rising from specialized software developers and regional manufacturers serving price-sensitive institutions.
Small Animal Imaging Competitive Insights
| Dimension | Description |
|---|---|
| Market Structure | Moderately concentrated, with a core group of global OEMs and a long tail of regional and specialist vendors |
| Innovation Focus | Multimodal integration, AI-enabled reconstruction, and cloud-based image analysis |
| M&A Activity | Partnerships and portfolio consolidation targeting software and contrast agent capabilities |
Source: Healthcare Industry Insights Analysis, 2026
Market Structure and Concentration
Our findings suggest that the market is moderately concentrated, with leading hardware manufacturers holding significant installed bases. Competitive intensity is rising from specialized software developers and regional manufacturers serving price-sensitive institutions.
Innovation Priorities
We observed that vendors are prioritizing multimodal integration, reducing scan times, and improving quantification consistency. Software differentiation increasingly determines purchasing decisions alongside hardware performance.
Partnership and Consolidation Activity
During our market evaluation, we noticed that partnerships such as the 2025 collaboration between MARS Bioimaging and Medilumine indicate a trend toward combining hardware, imaging agents, and analytical capabilities into integrated offerings.
Pricing and Service Models
Based on research conducted by our analysts, we found that service-led and shared-access models are gaining traction as institutions seek to manage capital exposure. Vendors offering maintenance, validation, and training bundles are strengthening customer retention.
Key Market Players in the Small Animal Imaging
Key companies active in the global Small Animal Imaging include:
Latest Small Animal Imaging Industry Developments
We found that recent product launches within the Small Animal Imaging are concentrated on key technological advancements, reflecting the industry's broader transition.
| Date | Summary | Source |
|---|---|---|
| May 2025 | Hallmarq published guidance on total cost of ownership for its 1.5T veterinary small animal MRI solutions. | Official Announcement |
| January 2025 | MARS Bioimaging and Medilumine announced a partnership to advance imaging capabilities. | Official Announcement |
| January 2025 | LI-COR Biosciences: LI-COR launched the Pearl Trilogy Imaging System for in vivo small animal imaging applications. | Official Source |
| January 2025 | RWD Life Science offers a Small Animal In Vivo Imaging System for preclinical research. | Official Announcement |
| January 2025 | University of Wisconsin Carbone Cancer Center: The Small Animal Imaging and Radiotherapy Facility provides preclinical imaging resources for cancer research. | Official Announcement |
| January 2025 | Licorbio: LI-COR published getting-started guidance for its acquisition software used with small animal imaging systems. | Official Announcement |
Source: Healthcare Industry Insights Analysis, 2026
Key Benefits for Small Animal Imaging Stakeholders
Stakeholder
Our assessment indicates that enterprise leaders can improve study efficiency by adopting integrated imaging workflows that reduce repeat animal handling. Standardized quantification across sites supports reproducibility in multi-center preclinical programs.
Stakeholder
Based on research conducted by our analysts, we found that investors can target software and veterinary segments growing at 5.7% and 11.5% CAGR, respectively, over 2026–2035. Diversified exposure across regions balances the mature North American base against faster Asia-Pacific and Middle East expansion.
Stakeholder
We found that technology vendors offering interoperable analytics and service bundles can differentiate in a market where software is the fastest-growing offering. Partnerships with contrast agent developers and CROs widen addressable demand.
Conclusion and Recommendations
Long-Term Outlook
Our findings suggest that the market will expand from USD 3.4 Billion in 2026 to USD 6.4 Billion by 2035 at a 7.2% CAGR. Mature hardware replacement cycles will continue, but growth will increasingly reflect software and veterinary adoption.
Strategic Positioning Recommendations
We recommend that vendors align hardware roadmaps with software platforms that deliver recurring analytical value. Positioning around multimodal integration will strengthen competitiveness across pharmaceutical and CRO buyers.
Investment Attractiveness
Healthcare Industry Insights's analysis indicates that the market offers attractive risk-adjusted returns, particularly in software and emerging regional capacity build-outs. Investors should weigh these against currency and tariff exposure in Latin America.
Market Shifts and Key Risks
We observed that consolidation, pricing pressure from regional manufacturers, and potential pharmaceutical R&D budget contractions represent the main risks. Compliance mandates provide a stable demand floor but do not guarantee above-trend expansion.
Growth Pathways
Our assessment indicates that the primary growth pathways shift toward high-CAGR expansion segments, namely software analytics, veterinary and gene therapy tracking, and Asia-Pacific and Middle East capacity. Stakeholders who build capability in these areas will capture disproportionate share of the USD 3 Billion absolute opportunity between 2026 and 2035.
Frequently Asked Questions
Consolidated Source Table
| Source / Organization | URL |
|---|---|
| MARS Bioimaging Official Announcement | https://medilumine.com/mars-bioimaging-and-medilumine-announce-partnership?srsltid=AU7gw4UWrKaqoGtOwMojWD2fJED2nwkB7tjxrN06WKflTLzfRb6AqWPP |
| LI-COR Biosciences Official Announcement | https://www.licorbio.com/pearl |
| RWD Life Science Official Announcement | https://www.rwdstco.com/product-item/small-animal-in-vivo-imaging-system/ |
| Hallmarq Official Announcement | https://hallmarq.net/us/2025/05/19/1-5t-veterinary-mri-calculating-the-total-cost-of-ownership/ |
| Cancer Official Announcement | https://cancer.wisc.edu/research/resources/sairf/ |
| Youtube Official Announcement | https://www.youtube.com/watch?v=HM9aUCTIYK4 |
| Licorbio Official Announcement | https://www.licorbio.com/support/contents/software/licor-acquisition/getting-started.html |
| Liberiatenders Official Announcement | https://www.liberiatenders.com/keywords/small-animal-imaging-system-tenders/ |
Methodology Note: Market sizing figures are HII industry-derived estimates based on triangulated supply-side manufacturer revenue analysis, demand-side consumption assessment, and macro-level trade and investment tracking across publicly available corporate disclosures, government statistics, and regulatory filings. All estimates are labeled as such where no single publicly verifiable dataset exists for this exact market definition and scope.
Summarize This Report:
You May Also Like
Custom Market Research Services
We will customise the research for you, in case the report listed above does not meet with your exact requirements. Get 30% free customisation on this report.